Advertisement
Ms. Huber brings more than 20 years of financial experience, predominatelyin the medical device industry, to ConforMIS. Most recently, Ms. Huber servedas Vice President and Controller at NxStage Medical where she was instrumentalin building the financial and administrative infrastructure that led to thecompany's initial public offering, secondary financing and acquisition ofMedisystems Corporation.
Advertisement
"We are extremely pleased to welcome Judy as the final member of theConforMIS executive team," said Chairman and CEO Philipp Lang, MD. "Judy joinsConforMIS at an exciting time in our company's history as we've seen demandacross the globe for our line of patient-specific implants increasesubstantially. Her experience in building financial infrastructure to supportgrowth on both the operations and commercialization fronts will play a keyrole as we head into the second half of 2008 and beyond."
Prior to joining NxStage Medical, Ms. Huber spent more than nine years invarious financial positions with C. R. Bard and AVE/Medtronic. She supportedmultiple divisions focused on improving the economic efficiencies of theirmanufacturing operations.
"I'm looking forward to working with an accomplished team of executives atsuch an important and exciting time in ConforMIS' growth," said Ms. Huber."Delivering on the opportunity to build a robust financial capability forConforMIS will enable the company to continue on the path to becoming a majorplayer in the orthopedic market."
Ms. Huber earned a B.S. in Accounting from the State University of NewYork at Geneseo and an M.B.A. from the Babson College. She is also a CertifiedManagement Accountant.
About ConforMIS, Inc.
ConforMIS, Inc. is a privately held company incorporated in 2004 thatdevelops and commercializes medical devices for the treatment ofosteoarthritis and joint damages. The Company's novel and scaleable'image-to-implant' process is comprised of two related technology platforms.iFit(TM) Technology enables the creation of conforming, patient-specificimplants that are precisely sized and shaped to match the 3D topography of thepatient's bone surfaces. The iJig(TM) Instrumentation enables the creation ofnovel, disposable cutting and placement guides that simplify and improve thesurgical process.
Both platforms are supported by proprietary, intellectual propertyconsisting of more than 120 issued patents or pending patent applications thatspan imaging software, image processing, implant design, surgical techniquesand instrumentation.
To date, ConforMIS has developed a comprehensive line of minimallytraumatic, bone and cartilage-preserving knee implants and instrumentationdesigned to address all stages of osteoarthritis, the most common reason forknee replacement surgery. Each device has been cleared by the U.S. Food andDrug Administration for marketing in the U.S.
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.ConforMIS, Inc. Contact: Jong Lee Senior Vice President, Marketing 781-345-9107 Media Contact: Sally Bain Racepoint Group 781-487-4647 [email protected]
SOURCE ConforMIS, Inc.
